Sanofi, Regeneron lose US patent challenge to Amgen cholesterol drug

Sanofi, Regeneron lose US patent challenge to Amgen cholesterol drug

A U.S. jury on Monday said patents owned by Amgen Inc on its cholesterol drug Rapatha are valid, rejecting a challenge by Regeneron Pharmaceuticals Inc and Sanofi SA, Bloomberg reported.

A logo is seen in front of the entrance at the headquarters of French drugmaker Sanofi in Paris
FILE PHOTO: A logo is seen in front of the entrance at the headquarters French drugmaker Sanofi in Paris October 30, 2014. REUTERS/Christian Hartmann

REUTERS: A U.S. jury on Monday said patents owned by Amgen Inc on its cholesterol drug Repatha are valid, rejecting a challenge by Regeneron Pharmaceuticals Inc and Sanofi SA, Bloomberg reported.

Sanofi and Regeneron had stipulated that if the Amgen patents were valid their jointly developed cholesterol drug Praluent infringed them.

(This story corrects spelling of Repatha in paragraph 1)

(Reporting by Jan Wolfe; Editing by Cynthia Osterman)

Source: Reuters

Bookmark